Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 78415-72-2
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Bag,Drum
Delivery Time: 7-15 days
Payment Terms: L/C, D/A, T/T, Western Union
Supply Ability: TON
CAS NO:: |
78415-72-2 |
Appearance:: |
Off-white Solid |
Molecular Formula:: |
C12H9N3O |
Molecular Weight:: |
211.21900 |
EINECS NO:: |
278-903-6 |
MDL NO:: |
MFCD00133539 |
CAS NO:: |
78415-72-2 |
Appearance:: |
Off-white Solid |
Molecular Formula:: |
C12H9N3O |
Molecular Weight:: |
211.21900 |
EINECS NO:: |
278-903-6 |
MDL NO:: |
MFCD00133539 |
Product Description:
Product Name: Milrinone CAS NO: 78415-72-2
Synonyms:
1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile;
6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile;
2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile;
Chemical & Physical Properties:
Appearance: Off-white solid
Assay :≥99.0%
Density: 1.28 g/cm3
Boiling Point: 448.7℃ at 760 mmHg
Melting Point: >300℃
Flash Point: 225.2℃
Stability: Stable. Incompatible with strong oxidizing agents.
Storage Condition: 2-8℃
Safety Information:
RTECS: DW1762000
Hazard Class: 6.1(b)
Safety Statements: S36/37/39-S45
HS Code: 2933399090
WGK Germany: 3
Packing Group: III
RIDADR: UN 2811
Risk Statements: R23/24/25
Hazard Code: T
Milrinone, commonly known and marketed under the brand name Primacor, is a medication used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, recent studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.
Overall, milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.